Please login to the form below

Not currently logged in
Email:
Password:

Michael Wyzga OncoMed board

He brings financial experience from Genzyme

Michael Wyzga OncoMedOncoMed has appointed industry veteran Michael Wyzga to the company's board of directors.

The cancer specialist is looking to make the most of Wyzga's years in the industry as it prepares to advance the development of its five drug candidates, with several new filings planned for 2014.

This experience includes serving as chief financial officer of the biotech Genzyme from 1998 to 2011, when the company was acquired by Sanofi in what was the second-largest acquisition in biotech history.

He is currently president and CEO of biopharma company Radius Health having joined the company in December 2011.

"As a CEO of an emerging biopharmaceuticals company and previous chief financial officer of one of the leading biotechnology companies in the world, Mike brings an excellent perspective to OncoMed's board following our successful initial public offering," said Paul Hastings, chairman and CEO of OncoMed.

In addition to its own prospects, OncoMed also has development deals with major pharma companies, including GlaxoSmithKline and Bayer.

23rd October 2013

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Say Communications

We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...